Home
    Disclaimer
    ← Back to 5-MeO-DALT
    5-MeO-DALT molecular structure

    5-MeO-DALT Stats & Data

    Psychedelic Research-chemical
    Foxtrot 5meodalt
    Chemical Class Phenethylamine
    Psychoactive Class Psychedelic
    Half-Life Unknown (subjective effects typically 2–4 h orally; smoked route peaks within minutes and resolves within ~45 min)

    Receptor Profile

    Receptor Actions

    Agonists
    5-HT1A receptor agonist (full)
    5-HT2A receptor agonist (full)
    5-HT2B receptor agonist
    5-HT2C receptor agonist
    Inhibitors
    Dopamine reuptake inhibitor
    Serotonin reuptake inhibitor

    Effect Profile

    Curated + 69 Reports
    Psychedelic 8.8

    Strong visuals, headspace, auditory effects, and body load

    Visual Intensity×3
    1010
    Headspace Depth×3
    105.5
    Auditory Effects×1
    1010
    Body Load / Somatic Effects×1
    109.3
    Catalog Erowid
    Based on reports from:
    Effect Index Restless Mind — nervewing TiHKAL TiHKAL #56: 5-MeO-DALT Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 5-MeO-DALT The Drug Users Bible 5-MeO-DALT

    Duration Timeline

    Bluelight
    Onset Comeup Peak Offset After Effects
    Oral
    10-15 minutes
    15-19 minutes
    1-1.5 hours
    1-2 hours
    Total: 3-6 hours
    Insufflated
    4-10 minutes
    10-15 minutes
    1-1.5 hours
    1-2 hours
    Smoked
    0 minutes
    0 minutes
    0-6 minutes
    6-12 minutes
    6-12 minutes
    Total: 15-20 minutes hours

    Tolerance & Pharmacokinetics

    drugs.wiki
    Half-Life
    Unknown (subjective effects typically 2–4 h orally; smoked route peaks within minutes and resolves within ~45 min)
    Addiction Potential
    Low; no evidence of physical dependence. Some users report psychological habituation with frequent use.

    Tolerance Decay

    Full tolerance 1d Half tolerance 7d Baseline ~14d

    Tolerance data are extrapolated from general psychedelic tolerance patterns; specific pharmacodynamic tolerance studies for 5-MeO-DALT are lacking. Users commonly report diminished effects with re-dosing on the same day and partial tolerance persisting for several days to a week.

    Cross-Tolerances

    Other tryptamines (e.g., DMT, 5-MeO-MiPT)
    60% ●○○
    Classical psychedelics (LSD, psilocin)
    50% ●○○

    Experience Report Analysis

    Erowid
    69 Reports
    2004–2017 Date Range
    56 With Age Data
    30 Effects Detected

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Effect Analysis

    Erowid

    Effects aggregated from 69 experience reports (69 Erowid)

    69 Reports
    30 Effects Detected
    10 Positive
    11 Adverse
    9 Neutral

    Effect Sentiment Distribution

    Confidence Distribution

    Positive Effects 10

    Stimulation 46.4% 70%
    Music Enhancement 40.6% 70%
    Euphoria 40.6% 70%
    Color Enhancement 34.8% 70%
    Tactile Enhancement 31.9% 70%
    Focus Enhancement 30.4% 70%
    Empathy 27.5% 70%
    Body High 27.5% 70%
    Introspection 10.1% 70%
    Creativity Enhancement 7.2% 70%

    Adverse Effects 11

    Anxiety 42.0% 70%
    Confusion 27.5% 70%
    Muscle Tension 24.6% 70%
    Nausea 23.2% 70%
    Increased Heart Rate 18.8% 70%
    Pupil Dilation 10.1% 70%
    Jaw Clenching 8.7% 70%
    Sweating 7.2% 70%
    Motor Impairment 7.2% 70%
    Headache 5.8% 70%
    Memory Suppression 4.3% 70%

    Dose-Response Correlation

    How effect frequency changes across dose levels

    View data table
    Effect Heavy (n=23)
    Visual Distortions 78.3%
    Anxiety 60.9%
    Stimulation 56.5%
    Music Enhancement 52.2%
    Focus Enhancement 47.8%
    Euphoria 39.1%
    Empathy 39.1%
    Nausea 34.8%
    Tactile Enhancement 34.8%
    Body High 30.4%
    Confusion 30.4%
    Color Enhancement 26.1%
    Increased Heart Rate 26.1%
    Introspection 26.1%
    Muscle Tension 26.1%

    Dose–Effect Mapping

    Experience Reports

    How reported effects shift across dose tiers, based on 69 experience reports.

    Limited tier coverage — most reports fall within the Heavy range. Effects at other dose levels may not be represented.

    Oral dose range: 30.0–75.0 mg (median 40.0 mg)
    Effect Heavy (n=23)
    visual distortions
    78%
    anxiety
    61%
    stimulation
    56%
    music enhancement
    52%
    focus enhancement
    48%
    euphoria
    39%
    empathy
    39%
    nausea
    35%
    tactile enhancement
    35%
    body high
    30%
    confusion
    30%
    color enhancement
    26%
    increased heart rate
    26%
    introspection
    26%
    muscle tension
    26%
    open-eye visuals
    22%
    auditory effects
    22%
    hospital
    22%
    closed-eye visuals
    22%
    dissociation
    22%

    Showing top 20 of 31 effects

    Dosage Distribution

    Dose distribution from experience reports

    Median: 40.0 mg IQR: 30.0–75.0 mg n=37

    Real-World Dose Distribution

    62K Doses

    From 80 individual dose entries

    Oral (n=60)

    Median: 30.0mg 25th: 24.0mg 75th: 60.0mg 90th: 86.5mg
    mg/kg median: 0.507 mg/kg 75th: 0.932

    Smoked (n=8)

    Median: 17.5mg 25th: 10.0mg 75th: 20.0mg 90th: 21.5mg
    mg/kg median: 0.22 mg/kg 75th: 0.353

    Common Combinations

    Most co-occurring substances in experience reports

    Form / Preparation

    Most common forms and preparations reported

    Body-Weight Dosing

    Dose relative to body weight from reports with weight data

    Median: 0.63 mg/kg IQR: 0.456–1.071 mg/kg n=34

    Redose Patterns

    Redosing behavior across 58 reports

    19.0% Redosed
    1.3 Avg Doses
    45m Median Interval
    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Austria Since January 1, 2012, 5-MeO-DALT is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
    China As of October 2015 5-MeO-DALT is a controlled substance in China.
    Germany 5-MeO-DALT is controlled under the NpSG ( New Psychoactive Substances Act ) as of July 18, 2019. Production and import with the aim to place it on the market, administration to another person, placing it on the market and trading is punishable. Possession is illegal but not punishable. The legislator considers it possible that orders of 5-MeO-DALT are punishable as an incitement to place it on the market.
    Japan 5-MeO-DALT became a controlled substance in Japan from April 2007, by amendment to the Pharmaceutical Affairs Law.
    Singapore 5-MeO-DALT is listed in the Fifth Schedule of the Misuse of Drugs Act (MDA) and therefore illegal in Singapore as of May 2015.
    Slovakia 5-MeO-DALT is a Schedule I substance in Slovakia as of December 1, 2021
    Sweden Sveriges riksdag added 5-MeO-DALT to schedule I ("substances, plant materials and fungi which normally do not have medical use") as narcotics in Sweden as of May 1, 2012, published by Medical Products Agency in their regulation LVFS 2012:6 listed as 5-MeO-DALT N-allyl-N-2-(5-metoxi-1H-indol-3-yl)etyl-prop-2-en-1-amin.
    Switzerland 5-MeO-DALT is a controlled substance specifically named under Verzeichnis E.
    United Kingdom 5-MeO-DALT became a Class A drug in the UK on January 7, 2015 after an update to the tryptamine blanket ban.
    United States 5-MeO-DALT is not scheduled at the federal level in the United States, but it is likely that it could be considered an analog of 5-Meo-DiPT, which is a controlled substance in USA, or an analog of another tryptamine, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.
    United States - Florida 5-MeO-DALT is a Schedule I controlled substance in the state of Florida, making it illegal to buy, sell, or possess.

    Harm Reduction

    drugs.wiki

    Potency is moderate by mass but inter-individual response is erratic; weigh doses on an accurate 0.001 g scale and titrate cautiously to avoid accidental high dosing. Rapid oral onset (often within 10–30 minutes) and a short peak make premature redosing tempting; wait at least 90 minutes after a first dose to assess the plateau. Insufflation is widely reported as irritating, with a bitter/chemical drip and unpredictable intensity; avoid large lines and consider oral use instead to reduce overdose risk. Vaporization/smoking produces an immediate, intense but brief peak; begin with 1–2 mg test puffs and use precise measurement or volumetric dosing to avoid overshooting. Combining with MAOIs significantly raises risk due to potentiation of tryptamines; avoid Syrian rue/ayahuasca or pharmaceutical MAOIs near 5-MeO-DALT sessions. As a serotonergic psychedelic, it can interact adversely with SSRIs/SNRIs, tramadol, DXM, lithium, and other serotonergics; these combinations increase serotonin toxicity risk. Some users report headaches, chest tightness, and vasoconstriction; maintain gentle hydration and avoid hot environments and stimulant combinations. A minority report dysphoria, confusion, derealization, or panic; use in a safe setting with a sober sitter if inexperienced, and avoid if you have a personal/family history of psychosis or bipolar disorder. Test your sample (reagents, and where available GC/MS or FTIR drug checking) to rule out mislabeling/adulterants; ‘research chemical’ markets are inconsistent. Effects appear to exhibit cross-tolerance with other psychedelics; spacing sessions by at least 1–2 weeks helps restore sensitivity and reduces psychological strain. Avoid driving or hazardous activities until fully baseline, as perception and coordination may be altered beyond the subjective ‘come-down.’

    References

    Data Sources

    Cited References

    Drugs.wiki References

    ← Back to 5-MeO-DALT